Wave Life Sciences, Duchenne muscular dystrophy
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene.
WSAV Savannah on MSN3d
Muscular Dystrophy Association’s inaugural Clays for a CureThe Muscular Dystrophy Association (MDA) held its first-ever Clays for a Cure event on Friday, Sept. 20. Check out the photos ...
Discover Avidity Biosciences' groundbreaking patent for treating facioscapulohumeral muscular dystrophy (FSHD) using a novel polynucleic acid conjugate targeting the DUX4 gene.
Brodie Pankhurst suffers from Duchenne muscular dystrophy, which progressively weakens his muscles. The cruel illness has ...
Six-year-old Cooper Wood was diagnosed with Duchenne muscular dystrophy earlier this year. When his parents applied for a one ...
If you notice traffic backing up and firefighters out at an intersection on Friday and Saturday, don’t worry — it’s all for a ...
The Cambridge Professional Fire Fighters’ Association held their annual Muscular Dystrophy Boot Drive on Saturday.
Faith Fortenberry, 13, of Hubbard, was one of 100 guests flown to the nation’s capital by the Muscular Dystrophy Association ...
Meet Sehba Shah, Pakistan's inspiring woman chess player who lives with muscular dystrophy yet dreams high above the ...
Pratteln, Switzerland, September 24, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing ...
Muscular Dystrophy UK is the leading charity for more than 110,000 children and adults in the UK living with one of over 60 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback